Anixa Biosciences to Present at SITC Annual Meeting

SAN JOSE, Calif., Oct. 29, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it will present data from its ongoing studies utilizing Cchek™, Anixa's artificial intelligence (AI) driven early cancer detection technology, at the 33rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC).  Cutting-edge research will be presented by experts in the field of applied cancer immunotherapy and translational research.  Anixa will be presenting both an oral and poster presentation.  The meeting will be held November 9–11, 2018 in Washington, D.C. and will be attended by both U.S. and international researchers, regulators, and healthcare professionals who are involved in cancer research and clinical care. 

Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)

Oral Presentation:

Title: Using artificial intelligence to distinguish subjects with prostate cancer (PCa) from benign prostatic hyperplasia (BPH) through immunophenotyping of MDSCs and lymphocyte cell populations
Presenter: George A. Dominguez, Ph.D.
Abstract ID: 10805
Session: Concurrent Session 215: Myeloid Derived Suppressor Populations
Date and Time: Saturday, November 10, 2018; 6:15 PM – 6:30 PM ET

Poster Presentation:

Title: Using artificial intelligence to distinguish subjects with prostate cancer (PCa) from benign prostatic hyperplasia (BPH) through immunophenotyping of MDSCs and lymphocyte cell populations
Authors: George A. Dominguez, Ph.D.; John Roop; Alex Polo; Anthony J. Campisi; Dmitry I. Gabrilovich, MD, Ph.D.; Amit Kumar, Ph.D.
Poster Number: O2
Category: Biomarkers and Immune Monitoring
Location: Walter E. Washington Convention Center, Hall E
Date and Time: Friday, November 9, 2018 (8 AM – 8 PM ET) and Saturday, November 10, 2018 (8 AM – 8:30 PM ET); Presentation – Saturday, November 10, 2018 (12:20 – 1:50 PM ET and 7 – 8:30 PM ET)

To receive a copy of the presentations, please email your request to starting November 11, 2018 and include your name, title, and contact information.

"We are pleased to be presenting at SITC.  As SITC restricts detailed discussion of presentation contents ahead of the conference, we will make presentation information available after the conference," stated Dr. Amit Kumar, President and CEO of Anixa Biosciences. 

Society for Immunotherapy of Cancer (SITC)
The Society for Immunotherapy of Cancer (SITC) ( is a 501(c)(3) not-for-profit organization that has been serving scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world since 1984.  With more than 2,000 members, SITC is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.  SITC aims to make cancer immunotherapy a standard of care and the word "cure" a reality for cancer patients everywhere.

About Anixa Biosciences, Inc.
Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer.  Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed.  It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy.  It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.  Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization.  Additional information is available at

Forward-Looking Statements:  Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results.  We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements.  Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.  These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.  You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.


Cision View original content to download multimedia:

SOURCE Anixa Biosciences, Inc.